Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) posted its earnings results on Monday. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.10, FiscalAI reports. The firm had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%.

Intellia Therapeutics Stock Up 2.3%

Intellia Therapeutics stock opened at $14.42 on Tuesday. Intellia Therapeutics has a twelve month low of $6.83 and a twelve month high of $28.25. The firm has a 50 day moving average price of $13.67 and a 200-day moving average price of $12.22. The company has a market capitalization of $1.74 billion, a P/E ratio of -3.77 and a beta of 1.93.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 28th. Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a research note on Monday, April 27th. Truist Financial raised shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group boosted their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Finally, Chardan Capital boosted their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.77.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently modified their holdings of NTLA. Virtu Financial LLC purchased a new stake in Intellia Therapeutics in the 4th quarter worth approximately $245,000. Invesco Ltd. grew its holdings in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after purchasing an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Intellia Therapeutics by 20.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after purchasing an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at $90,000. Finally, XTX Topco Ltd bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at $402,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.